In the MASLD (metabolic dysfunction-associated steatotic liver disease) trial, retatrutide reduced liver fat by up to 82.4% at the 12mg dose level
H&E and IHC slides were scanned at 40X magnification with the Hamamatsu NanoZoomer and visualized with the NDP.View2Plus software for brightfield microscopy cell counting
Patients who eat large meals, consume acidic foods, or lie down shortly after eating are particularly prone to symptoms while on GLP-1 therapy
Aiming for specific targets can make a huge difference
GLP-1 drugs work partly by slowing the stomach and blunting appetite, and during the first weeks and after every dose increase they commonly cause nausea, vomiting, and diarrhea
Before heading back to school, Wellstar health experts say its more important than ever prioritize your childs physical and emotional well-being